Ark signs South Korean sales deal for Kerraboot ulcer device:
This article was originally published in Clinica
Executive Summary
Ark Therapeutics, of London, UK, has signed an exclusive marketing agreement for its Kerraboot leg and foot ulcer management device in South Korea. Local healthcare products distributor BL&H Co has acquired sales and marketing rights in return for a double-digit royalty to Ark. BL&H Co will be responsible for securing product reimbursement from the South Korean regulators. According to Ark, there are about 2 million diabetics in the country, of whom 300,000 could be expected to have a leg or foot ulcer at any one time.